Idexx Laboratories Inc. (IDXX) Shares Sold by Harvey Investment Co. LLC
Harvey Investment Co. LLC decreased its stake in shares of Idexx Laboratories Inc. (NASDAQ:IDXX) by 0.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 138,731 shares of the company’s stock after selling 234 shares during the period. Idexx Laboratories accounts for approximately 2.8% of Harvey Investment Co. LLC’s portfolio, making the stock its 11th largest position. Harvey Investment Co. LLC owned 0.15% of Idexx Laboratories worth $12,883,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in IDXX. Huntington National Bank raised its stake in shares of Idexx Laboratories by 112.1% in the second quarter. Huntington National Bank now owns 1,190 shares of the company’s stock valued at $111,000 after buying an additional 629 shares in the last quarter. Nordea Investment Management AB acquired a new stake in shares of Idexx Laboratories during the second quarter valued at about $176,000. Canada Pension Plan Investment Board acquired a new stake in shares of Idexx Laboratories during the first quarter valued at about $196,000. Strs Ohio acquired a new stake in shares of Idexx Laboratories during the second quarter valued at about $196,000. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Idexx Laboratories during the second quarter valued at about $204,000. 91.58% of the stock is owned by hedge funds and other institutional investors.
Idexx Laboratories Inc. (NASDAQ:IDXX) traded up 0.02% during mid-day trading on Wednesday, hitting $112.95. The company’s stock had a trading volume of 307,990 shares. The company’s 50 day moving average is $111.64 and its 200-day moving average is $94.79. The stock has a market cap of $10.11 billion, a P/E ratio of 51.20 and a beta of 0.41. Idexx Laboratories Inc. has a 52-week low of $63.48 and a 52-week high of $115.06.
Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.12. Idexx Laboratories had a negative return on equity of 414.67% and a net margin of 11.94%. The firm earned $467 million during the quarter, compared to analysts’ expectations of $444.83 million. During the same quarter in the previous year, the business earned $0.60 earnings per share. The company’s revenue was up 12.9% on a year-over-year basis. On average, equities analysts predict that Idexx Laboratories Inc. will post $2.36 EPS for the current fiscal year.
IDXX has been the subject of several research reports. Canaccord Genuity reiterated a “buy” rating and set a $120.00 price target on shares of Idexx Laboratories in a research note on Monday, August 22nd. Bank of America Corp. reiterated a “neutral” rating on shares of Idexx Laboratories in a research note on Thursday, September 29th. Stifel Nicolaus increased their price target on Idexx Laboratories from $120.00 to $125.00 and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Zacks Investment Research downgraded Idexx Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 4th. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research note on Wednesday, August 3rd. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Idexx Laboratories currently has a consensus rating of “Buy” and a consensus price target of $105.20.
In other news, Director William T. End sold 5,000 shares of the business’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $108.50, for a total value of $542,500.00. Following the completion of the transaction, the director now owns 53,564 shares in the company, valued at $5,811,694. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rebecca M. Henderson sold 9,924 shares of the business’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $110.43, for a total value of $1,095,907.32. Following the completion of the transaction, the director now owns 16,678 shares of the company’s stock, valued at approximately $1,841,751.54. The disclosure for this sale can be found here. 2.79% of the stock is owned by insiders.
Idexx Laboratories Company Profile
Receive News & Stock Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related stocks with our FREE daily email newsletter.